Payment overview · 2025
General Payments
$78.38
4 reported records · 4 companies
Healthcare provider profile · identity verified
Katherine Lisoni, MD
Allopathic & Osteopathic Physicians|Family Medicine · MISHAWAKA, IN · NPI 1780601351
Verified facts
What the public records show
CMS Open Payments records show Katherine Lisoni, MD received $78.38 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.95 | 33.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 24.1% | 1 | 2025 |
| Medline Industries LP | Unresolved — no canonical attribution shown | $17.35 | 22.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.23 | 20.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.53 | 3 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 38 |
| Alendronate Sodium | Alendronate Sodium | 168 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 45 |
| Lisinopril | Lisinopril | 159 | 50 |
| Ozempic | Semaglutide | 148 | 26 |
| Losartan Potassium | Losartan Potassium | 124 | 36 |
| Bupropion Xl | Bupropion Hcl | 119 | 31 |
| Jardiance | Empagliflozin | 107 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 37 |
| Omeprazole | Omeprazole | 98 | 22 |
| Gabapentin | Gabapentin | 90 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 24 |
| Famotidine | Famotidine | 63 | 18 |
| Metformin Hcl | Metformin Hcl | 59 | 20 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 51 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Spironolactone | Spironolactone | 48 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Allopurinol | Allopurinol | 40 | 11 |
| Fluconazole | Fluconazole | 40 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 15 |
| Furosemide | Furosemide | 35 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | 13 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 14 |
| Varenicline Tartrate | Varenicline Tartrate | 28 | 13 |
| Baclofen | Baclofen | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Vivitrol | Naltrexone Microspheres | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Prednisone | Prednisone | 17 | 17 |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $78.38 · 4 records | ABBVIE INC. | JARDIANCE, Omnipod, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error